NASDAQ: CDRX

Company Deals

Rallybio to Acquire Candid Therapeutics in $700M+ Merger – Creates Leading Autoimmune T‑Cell Engager Company

Fineline Cube Mar 5, 2026

Rallybio Corporation (NASDAQ: RLYB) and Candid Therapeutics, Inc. announced a definitive merger agreement whereby Rallybio will...

Company Deals

AstraGenomics and Kactus Forge Gene Editing Partnership – Global Commercial Rights and Manufacturing Scale-Up for Nucleic Acid Therapeutics

Company Drug

Ab&B Bio-Tech Wins FDA IND Approval for mRNA Mpox Vaccine – China’s First U.S.-Cleared Candidate Targets Immunocompromised Populations

Company Drug

Novo Nordisk’s CagriSema Fails Non‑Inferiority Test Against Lilly’s Zepbound in Phase III REDEFINE 4 Trial – 23% vs. 25.5% Weight Loss

Company

Bayer Reports EUR 45.6 Billion 2025 Sales – Nubeqa and Kerendia Drive Pharma Growth Amid Xarelto Patent Cliff